@article {Pham2021.02.26.21252327, author = {Thi Mui Pham and Hannan Tahir and Janneke H.H.M. van de Wijgert and Bastiaan Van der Roest and Pauline Ellerbroek and Marc J.M. Bonten and Martin C.J. Bootsma and Mirjam E. Kretzschmar}, title = {Interventions to control nosocomial transmission of SARS-CoV-2: a modelling study}, elocation-id = {2021.02.26.21252327}, year = {2021}, doi = {10.1101/2021.02.26.21252327}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Emergence of more transmissible SARS-CoV-2 variants requires more efficient control measures to limit nosocomial transmission and maintain healthcare capacities during pandemic waves. Yet, the relative importance of different strategies is unknown.Methods We developed an agent-based model and compared the impact of personal protective equipment (PPE), screening of healthcare workers (HCWs), contact tracing of symptomatic HCWs, and restricting HCWs from working in multiple units (HCW cohorting) on nosocomial SARS-CoV-2 transmission. The model was fit on hospital data from the first wave in the Netherlands (February until August 2020) and assumed that HCWs used 90\% effective PPE in COVID-19 wards and self-isolated at home for seven days immediately upon symptom onset. Intervention effects on the effective reproduction number (RE), HCW absenteeism and the proportion of infected individuals among tested individuals (positivity rate) were estimated for a more transmissible variant.Results Introduction of a variant with 56\% higher transmissibility increased {\textendash} all other variables kept constant {\textendash} RE from 0.4 to 0.65 (+63\%) and nosocomial transmissions by 303\%, mainly because of more transmissions caused by pre-symptomatic patients and HCWs. Compared to baseline, PPE use in all hospital wards (assuming 90\% effectiveness) reduced RE by 85\% and absenteeism by 57\%. Screening HCWs every three days with perfect test sensitivity reduced RE by 67\%, yielding a maximum test positivity rate of 5\%. Screening HCWs every three or seven days assuming time-varying test sensitivities reduced RE by 9\% and 3\%, respectively. Contact tracing reduced RE by at least 32\% and achieved higher test positivity rates than screening interventions. HCW cohorting reduced RE by 5\%. Sensitivity analyses for 50\% and 70\% effectiveness of PPE use did not change interpretation.Conclusions In response to the emergence of more transmissible SARS-CoV-2 variants, PPE use in all hospital wards might still be most effective in preventing nosocomial transmission. Regular screening and contact tracing of HCWs are also effective interventions, but critically depend on the sensitivity of the diagnostic test used.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMK was supported by ZonMw grant number 10430022010001. MK and HT were supported by ZonMw grant number 547001005 within the 3rd JPI ARM framework (Joint Programming Initiative on Antimicrobial Resistance) cofound grant no 681055 for the consortium EMerGE-Net). MB was supported by RECOVER (Rapid European COVID-19 Emergency research Response), which has received funding from the EU Horizon 2020 research and innovation programme (grant agreement number 101003589). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a modeling study which did not require IRB and/or ethics committee approvals. All data is publicly available.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code used in the manuscript are available from: https://github.com/htahir2/covid_intra-hospital_model https://data.rivm.nl/covid-19/COVID-19_prevalentie.json https://opendata.cbs.nl/statline/$\#$/CBS/nl/dataset/71857ned/table?ts=1517582466533 http://doi.org/10.5281/zenodo.3711575 http://doi.org/10.5281/zenodo.3711575 https://github.com/htahir2/covid_intra-hospital_model/blob/main/data/covid_patient_admissions_los_UMCU.csv AbbreviationsCOVID-19Coronavirus disease 2019HCWHealthcare workerICUIntensive-care unitLTCFLong-term care facilitiesPPEPersonal protective equipmentRT-PCRReverse transcriptase polymerase chain reactionREEffective reproduction numberRIVMRijksinstituut voor Volksgezondheid en Milieu (Dutch National Institute for Public Health and the Environment)SARS-CoV-2Severe acute respiratory syndrome coronavirus 2SEIRSusceptible-Exposed-Infectious-RecoveredUMCUUniversity Medical Center Utrecht}, URL = {https://www.medrxiv.org/content/early/2021/03/23/2021.02.26.21252327}, eprint = {https://www.medrxiv.org/content/early/2021/03/23/2021.02.26.21252327.full.pdf}, journal = {medRxiv} }